Q-Med Says $3B Medicis-Valeant Deal Violates Licensing Pact

Law360, New York (November 9, 2012, 5:29 PM EST) -- Q-Med AB launched a suit in New York federal court Wednesday seeking to prevent Medicis Pharmaceutical Corp. from transferring marketing rights for Q-Med's skin care products to rival Valeant Pharmaceuticals International Inc., which has announced plans to buy Medicis for $2.6 billion.

Sweden-based Q-Med claims Medicis is going ahead with the Valeant deal despite being informed that Q-Med won't consent to any deal that transfers Medicis' exclusive North American marketing rights for Q-Med dermal filler products Restylane, Perlane and Sub-Q to Valeant, which directly competes with...
To view the full article, register now.